How early plasmid design and CDMO partnership can set you up for success in cell or gene therapy manufacturing

Abstract

Beginning with the end in mind: how early plasmid design and CDMO partnership can set you up for success in cell or gene therapy manufacturing

Plasmids are important tools for building gene therapies, but substantial challenges exist for manufacturing a plasmid-based therapy – making it crucial for innovators to be aware of best practises.

Roisin McGuigan, Editor, BioInsights, talks to OXGENE’s Richard Parker-Manuel, PhD, Group Leader for Plasma Engineering & Production &, Qian Liu, PhD, Head of Engineering & Production about how careful plasmid design through promoter/capsid discovery and plasmid engineering early on in therapeutic development can help ensure that an innovator begins their journey with the right tools – and how an early CDMO partnership can foster success later down the line.